A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer

Suppression of Ovarian Function Trial (SOFT)

  • Biological Material / Translational Research

  • Substudies Info

    Co-SOFT Substudy

    The Cognitive Function Substudy is investigating cognitive function for patients participating in the SOFT trial in selected centers.


    SOFT-EST Substudy

    This Substudy investigates estrogen levels at different timepoints during the first 4 years of protocol treatment among patients receiving triptorelin plus either tamoxifen (arm B) or exemestane (arm C). The substudy is open for selected centers.

  • Results & Publications


Study Chairs
BIG: Dr. Prue Francis - Melbourne, Australia
US Intergroup: Dr. Gini Fleming - Chicago, USA

Dr. Meredith Regan

Trial Coordinator
Meredith Kissel, Dorene Polizzi

Data Managers
Monica Greco, Adriana Mora de Karausch

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email:  This email address is being protected from spambots. You need JavaScript enabled to view it.

Date of Activation
August 4, 2003

Date of Closure
January 31, 2011

Targeted Accrual
3000 patients

Final Accrual
3066 patients

ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland

Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org

Member Login